Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26318334 | 0.78 | HPGD (0.30) | — | |
| SCHEMBL26311730 | 0.75 | PRSS1 (0.34) | — | |
| SCHEMBL7073104 | 0.67 | ALDH1A1 (0.35) | ALDH1A1MEN1CYP3A4GAAKMT2A | |
| SCHEMBL12852620 | 0.67 | SMN1; SMN2 (0.42) | KMT2A | |
| SCHEMBL16488283 | 0.67 | TERT (0.33) | — | |
| SCHEMBL19187802 | 0.66 | ALDH1A1 (0.33) | ALDH1A1CYP1A2CYP2D6CYP2C19CYP3A4 | |
| SCHEMBL26544451 | 0.66 | NR1H4 (0.50) | ALDH1A1CYP1A2MEN1KMT2A | |
| SCHEMBL10332053 | 0.66 | SMN1; SMN2 (0.43) | CYP1A2MEN1KMT2A | |
| SCHEMBL14514331 | 0.66 | CNR1 (0.37) | CYP1A2CYP2D6CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL14446719 | 0.65 | HTT (0.38) | ALDH1A1CYP1A2CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | ALDH1A1 4544/4885CYP1A2 3880/4885CYP2D6 3871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.